Astellas Pharma Inc. Unsponsored ADR (ALPMY)

HEALTH CARE: PHARMACEUTICALS

60 WALL STREET NEW YORK, NY 10005

Astellas Pharma Inc. engages in the manufacture, marketing, and import/export of pharmaceutical products. It primarily focuses on the development of products in the areas of urology, immunology, inflammation, central nervous system, pain, diabetes, cancer, cardiovascular, and dermatology, as well as infectious diseases, including viral diseases. The company's products include Prograf, an immunosuppressant to prevent rejection in organ transplants; Protopic for the treatment of atopic dermatitis; Vesicare for the treatment of overactive bladder; Harnal for the treatment of benign prostatic hyperplasia; and Funguard, an antifungal agent. Its products also comprise Geninax, an oral quinolone antibacterial agent for respiratory tract and otorhinolaryngological infection pathogens; Celecox, a selective COX-2 lnhibitor for the rheumatoid arthritis; Lipitor for the treatment of hypercholesterolemia; Micardis for the treatment for hypertension; Gaster for the treatment for peptic ulcers and gastritis; Luvox, an antidepressant; Myslee for the treatment of insomnia; Cefzon, an oral cephalosporin antibiotic; Seroquel, an antipsychotic agent used for the treatment of schizophrenia; Dorner for chronic arterial occlusion; Nasea, a antagonist; and Targocid, a glycopeptide antibiotic. In addition, the company offers Lexiscan and Adenoscan, which are pharmacologic stress agents; AMEVIVE for the treatment of psoriasis; Vaprisol for euvolemic hyponatremia; AmBisome, an antifungal agent; Eligard for advanced prostate cancer; Locoid, a topical corticosteroid; Zineryt for acne; and Locobase for dry skin. It has licensing agreement with CoMentis, Inc. to research, develop, and commercialize beat- secretase inhibitors, including CTS-21166 for the treatment of Alzheimer's disease. Astellas Pharma operates in Japan, North America, Europe, and Asia. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Data as of 2021-05-01 10:26:19 -0400
Market Cap27.917 Billion Shares Outstanding1.862 Billion Avg 30-day Volume90.281 Thousand
P/E Ratio13.92635 Dividend Yield0.0 EPS1.04
Price/Sales2.4 Debt to Equity1.51 EBITDA2.83 Billion
Price to Book Value2.49 Forward PE Enterprise Value25.448 Billion
Total Cash2.806 Billion Current Debt4.489 Billion Gross Profit9.148 Billion
BETA0.0 52-week High/Low18.43 / 13.41 Next Earnings Date Price to Cash FLow (P/CF) 49.9653
Data provided by IEX Cloud
View SEC Filings from ALPMY instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 14 15 -6.67% 2 (0.12%) 2 (0.12%) 0.0%
13F shares: 3.423 Million 3.37 Million 1.57% 2.586 Million 2.515 Million 2.83%
% Ownership 0.1843 0.1814 1.6% 0.1392 0.1354 2.81%
New Positions: 2
Increased Positions 5 2 150.0% 2
Closed Positions 1 1 0.0%
Reduced Positions 2 6 -66.67% 2
Total Calls
Total Puts
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

Funds Holding ALPMY (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ALPMY BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ASTELLAS PHARMA INC-UNSP ADR ALPMY 2021-05-06 22:15:03 UTC -2.8479 2.8979 650000
ASTELLAS PHARMA INC-UNSP ADR ALPMY 2021-05-06 21:45:04 UTC -2.8479 2.8979 650000
ASTELLAS PHARMA INC-UNSP ADR ALPMY 2021-05-06 21:15:03 UTC -2.8479 2.8979 650000
ASTELLAS PHARMA INC-UNSP ADR ALPMY 2021-05-06 20:45:03 UTC -2.5611 2.6111 650000
ASTELLAS PHARMA INC-UNSP ADR ALPMY 2021-05-06 20:15:03 UTC -2.5611 2.6111 650000
ASTELLAS PHARMA INC-UNSP ADR ALPMY 2021-05-06 19:45:03 UTC -2.5611 2.6111 650000
ASTELLAS PHARMA INC-UNSP ADR ALPMY 2021-05-06 19:15:02 UTC -2.5611 2.6111 650000
ASTELLAS PHARMA INC-UNSP ADR ALPMY 2021-05-06 18:45:04 UTC -2.5611 2.6111 650000
ASTELLAS PHARMA INC-UNSP ADR ALPMY 2021-05-06 18:15:03 UTC -2.5611 2.6111 650000
ASTELLAS PHARMA INC-UNSP ADR ALPMY 2021-05-06 17:45:03 UTC -2.5611 2.6111 650000
ASTELLAS PHARMA INC-UNSP ADR ALPMY 2021-05-06 17:15:03 UTC -2.5611 2.6111 650000
ASTELLAS PHARMA INC-UNSP ADR ALPMY 2021-05-06 16:45:03 UTC -2.5611 2.6111 650000
ASTELLAS PHARMA INC-UNSP ADR ALPMY 2021-05-06 16:15:03 UTC -2.5611 2.6111 650000
ASTELLAS PHARMA INC-UNSP ADR ALPMY 2021-05-06 15:45:03 UTC -2.5611 2.6111 650000
ASTELLAS PHARMA INC-UNSP ADR ALPMY 2021-05-06 15:15:03 UTC -2.5611 2.6111 650000
ASTELLAS PHARMA INC-UNSP ADR ALPMY 2021-05-06 14:45:03 UTC -2.5611 2.6111 650000
ASTELLAS PHARMA INC-UNSP ADR ALPMY 2021-05-06 14:15:02 UTC -2.5611 2.6111 650000
ASTELLAS PHARMA INC-UNSP ADR ALPMY 2021-05-06 13:45:04 UTC -2.5611 2.6111 650000
ASTELLAS PHARMA INC-UNSP ADR ALPMY 2021-05-06 13:15:03 UTC -2.5611 2.6111 15000
ASTELLAS PHARMA INC-UNSP ADR ALPMY 2021-05-06 12:45:03 UTC -2.5611 2.6111 15000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments